Member Publications

Members of the NASH Roundtable™ contribute important research to the public domain through peer-reviewed articles in medical journals. Below is a selection of recent research co-authored by Roundtable members. For a comprehensive search of NASH-related research by Roundtable members and others, visit pubmed.gov.

Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores

Wu Y, Yang X, Morris HL, Gurka MJ, Shenkman EA, Cusi K, Bril F, Donahoo WT. JMIR Med Inform. 2022 Jun 6;10(6):e36997. doi: 10.2196/36997.

View Publication »

Breakthroughs in therapies for NASH and remaining challenges

Ratziu V, Francque S, Sanyal A. J Hepatol. 2022 Jun;76(6):1263-1278. doi: 10.1016/j.jhep.2022.04.002.

View Publication »

Bone morphogenetic protein 2 is a new molecular target linked to non-alcoholic fatty liver disease with potential value as non-invasive screening tool

Marañón P, Fernández-García CE, Isaza SC, Rey E, Gallego-Durán R, Montero-Vallejo R, de Cía JR, Ampuero J, Romero-Gómez M, García-Monzón C, González-Rodríguez Á. Biomark Res. 2022 May 25;10(1):35. doi: 10.1186/s40364-022-00383-3.

View Publication »

The Effect of Diabetes and Prediabetes on the Prevalence, Complications and Mortality in Non-alcoholic Fatty Liver Disease

Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH, Tan DJH, Khoo CM, Goh LH, Ling ZJ, Kulkarni A, Mak LL, Huang DQ, Chan M, Chew NW, Siddiqui MS, Sanyal AJ, Muthiah M. Clin Mol Hepatol. 2022 May 19. doi: 10.3350/cmh.2022.0096.

View Publication »

A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation

Vujkovic M, Ramdas S, Lorenz KM, Guo X, Darlay R, Cordell HJ, He J, Gindin Y, Chung C, Myers RP, Schneider CV, Park J, Lee KM, Serper M, Carr RM, Kaplan DE, Haas ME, MacLean MT, Witschey WR, Zhu X, Tcheandjieu C, Kember RL, Kranzler HR, Verma A, Giri A, Klarin DM, Sun YV, Huang J, Huffman JE, Townsend Creasy K, Hand NJ, Liu CT, Long MT, Yao J, Budoff M, Tan J, Li X, Lin HJ, Chen YI, Taylor KD, Chang RK, Krauss RM, Vilarinho S, Brancale J, Nielsen JB, Locke AE, Jones MB, Verweij N, Baras A, Reddy KR, Neuschwander-Tetri BA, Schwimmer JB, Sanyal AJ, Chalasani N, Ryan KA, Mitchell BD, Gill D, Wells AD, Manduchi E, Saiman Y, Mahmud N, Miller DR, Reaven PD, Phillips LS, Muralidhar S, DuVall SL, Lee JS, Assimes TL, Pyarajan S, Cho K, Edwards TL, Damrauer SM, Wilson PW, Gaziano JM, O’Donnell CJ, Khera AV, Grant SFA, Brown CD, Tsao PS, Saleheen D, Lotta LA, Bastarache L, Anstee QM, Daly AK, Meigs JB, Rotter JI, Lynch JA; Regeneron Genetics Center; Geisinger-Regeneron DiscovEHR Collaboration; EPoS Consortium; VA Million Veteran Program, Rader DJ, Voight BF, Chang KM. Nat Genet. 2022 Jun 2. doi: 10.1038/s41588-022-01078-z.

View Publication »

Clinical features and outcomes of NAFLD-related hepatocellular carcinoma – Authors’ reply

Tan DJH, Ng CH, Muthiah MD, Loomba R, Huang DQ. Lancet Oncol. 2022 Jun;23(6):e244. doi: 10.1016/S1470-2045(22)00265-0.

View Publication »

Prevalence estimation of significant fibrosis due to NASH in Spain combining transient elastography and histology

Calleja JL, Rivera-Esteban J, Aller R, Hernández Conde M, Abad J, Pericàs JM, Gonzalo Benito H, Serra MÁ, Escudero A, Ampuero J, Lucena A, Sánchez Y, Arias-Loste MT, Iruzubieta P, Romero-Gómez M, Augustin S, Crespo J. Liver Int. 2022 May 28. doi: 10.1111/liv.15323.

View Publication »

Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis

Sharpton SR, Podlaha O, Chuang JC, Gindin Y, Myers RP, Loomba R. Therap Adv Gastroenterol. 2022 May 18;15:17562848221098243. doi: 10.1177/17562848221098243.

View Publication »

Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD

Smirnova E, Muthiah MD, Narayan N, Siddiqui MS, Puri P, Luketic VA, Contos MJ, Idowu M, Chuang JC, Billin AN, Huss RS, Myers RP, Boyett S, Seneshaw M, Min HK, Mirshahi F, Sanyal AJ. Hepatology. 2022 May 13. doi: 10.1002/hep.32568.

View Publication »

Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study

Vali Y, Eijk R, Hicks T, Jones WS, Suklan J, Holleboom AG, Ratziu V, Langendam MW, Anstee QM, Bossuyt PMM; LITMUS Investigators. J Clin Med. 2022 May 11;11(10):2707. doi: 10.3390/jcm11102707.

View Publication »

Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018

Truong E, Yeo YH, Cook-Wiens G, Muthiah M, Yang JD, Sundaram V, Chang D, Todo T, Kim IK, Lu SC, Setiawan VW, Wong VWS, Harrison SA, Alkhouri N, Noureddin M. Hepatol Commun. 2022 May 9. doi: 10.1002/hep4.1981.

View Publication »

Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease

Chew NWS, Ng CH, Muthiah MD, Sanyal AJ. Curr Atheroscler Rep. 2022 May 4. doi: 10.1007/s11883-022-01027-5.

View Publication »

Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis

Sinakos E, Liava C, Loomba R. Ann Gastroenterol. 2022 May-Jun;35(3):213-225. doi: 10.20524/aog.2022.0704.

View Publication »

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

View Publication »

NAFLD/NASH

Bugianesi E, Petta S. J Hepatol. 2022 May 2:S0168-8278(22)00081-2. doi: 10.1016/j.jhep.2022.02.006.

View Publication »

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease

McGlinchey AJ, Govaere O, Geng D, Ratziu V, Allison M, Bousier J, Petta S, de Oliviera C, Bugianesi E, Schattenberg JM, Daly AK, Hyötyläinen T, Anstee QM, Orešič M. JHEP Rep. 2022 Mar 26;4(5):100477. doi: 10.1016/j.jhepr.2022.100477.

View Publication »

Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis

Ng CH, Lim WH, Hui Lim GE, Hao Tan DJ, Syn N, Muthiah MD, Huang DQ, Loomba R. Clin Gastroenterol Hepatol. 2022 May 2:S1542-3565(22)00439-6. doi: 10.1016/j.cgh.2022.04.014.

View Publication »

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)

Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.

View Publication »

Response to: “Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?”

Barb D, Cusi K. Obesity (Silver Spring). 2022 May;30(5):971-972. doi: 10.1002/oby.23422.

View Publication »

Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH

Vilalta A, Gutiérrez JA, Chaves S, Hernández M, Urbina S, Hompesch M. Endocrinol Diabetes Metab. 2022 May;5(3):e00335. doi: 10.1002/edm2.335.

View Publication »

Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science

Fouad Y, Palmer M, Chen M, Regev A, Banerjee R, Myers R, Riccio R, Torstenson R, Younes R, Arora PS, Landgren H, Karsdal MA, Blake M, Shapiro DA, Gruss HJ, Sheikh MY, Attia D, Bollipo S, Smith AD, Freilich B, Gish RG, Schuppan D. J Clin Transl Hepatol. 2022 Apr 28;10(2):374-382. doi: 10.14218/JCTH.2021.00408.

View Publication »

Greater ectopic fat deposition and liver fibroinflammation, and lower skeletal muscle mass in people with type 2 diabetes

Waddell T, Bagur A, Cunha D, Thomaides-Brears H, Banerjee R, Cuthbertson DJ, Brown E, Cusi K, Després JP, Brady M. Obesity (Silver Spring). 2022 Apr 27. doi: 10.1002/oby.23425.

View Publication »

JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk

Wyne KL, Litwin SE, Cusi K, Guyton JR. J Clin Lipidol. 2022 Mar-Apr;16(2):115-127. doi: 10.1016/j.jacl.2022.03.007.

View Publication »

A global view of the interplay between non-alcoholic fatty liver disease and diabetes.

Stefan N, Cusi K. Lancet Diabetes Endocrinol. 2022 Apr;10(4):284-296. doi: 10.1016/S2213-8587(22)00003-1.

View Publication »

Impaired Hepatic Mitochondrial Capacity in Nonalcoholic Steatohepatitis Associated With Type 2 Diabetes.

Gancheva S, Kahl S, Pesta D, Mastrototaro L, Dewidar B, Strassburger K, Sabah E, Esposito I, Weiß J, Sarabhai T, Wolkersdorfer M, Fleming T, Nawroth P, Zimmermann M, Reichert AS, Schlensak M, Roden M. Diabetes Care. 2022 Apr 1;45(4):928-937. doi: 10.2337/dc21-1758.

View Publication »

Read More »

Follow us on LinkedIn for publication updates